Narcolepsy and hypersomnolence — diagnosis and management in AU general practice

Narcolepsy and related hypersomnolence disorders are chronic neurological conditions of sleep-wake regulation that cause disabling excessive daytime sleepiness. They are often undiagnosed for years, misattributed to laziness or depression, and carry substantial personal and occupational burden. In Australia, diagnosis requires a sleep specialist, but general practice plays a critical role in recognition, appropriate referral, medication co-management, and monitoring for driving and safety obligations.

The common hypersomnolence disorders encountered in Australian general practice are narcolepsy Type 1 (with cataplexy — caused by orexin neuron loss), narcolepsy Type 2 (without cataplexy), and idiopathic hypersomnia (prolonged unrefreshing sleep with severe sleep inertia). The most common cause of excessive daytime sleepiness overall remains behavioural — insufficient sleep time — and this must be distinguished before pursuing specialist workup.

A. Core clinical — the AU general-practice framework

Assessment

The Australasian Sleep Association and eTG recommend structured assessment of any patient presenting with excessive daytime sleepiness.

Epworth Sleepiness Scale (ESS): A validated eight-item self-report questionnaire measuring likelihood of dozing in common situations; scores above 10 indicate abnormal sleepiness, above 16 severe. Use as a screening and monitoring tool in general practice.

History framework:

• EDS character — duration, frequency, refreshing versus non-refreshing nature of naps
• Cataplexy screening — “Have you ever felt your knees go weak or jaw drop unexpectedly when laughing or surprised?” Positive responses are highly specific for narcolepsy Type 1
• Sleep paralysis — brief inability to move on waking or falling asleep, with retained awareness
• Hypnagogic or hypnopompic hallucinations — vivid sensory experiences at sleep onset or waking
• Nocturnal sleep quality — frequent awakenings, restless legs, witnessed apnoeas
• Sleep diary — typically one to two weeks before specialist review
• Drug and alcohol history — sedating medications, alcohol, recreational substances
• Driving and occupational history — crash risk, shift work
• Mental health — depression and anxiety are common bidirectional comorbidities

Examination: Generally unremarkable in narcolepsy; direct examination toward excluding treatable mimics — check BMI, Mallampati score, and neck circumference for obstructive sleep apnoea risk; thyroid for hypothyroidism; neurological for rare secondary causes.

Investigations before specialist referral:

• TSH, FBC, ferritin (restless legs screening), B12, fasting glucose — to exclude treatable causes
• Home sleep study is NOT appropriate for narcolepsy diagnosis — it assesses for obstructive sleep apnoea only; formal laboratory polysomnography followed by MSLT is required

The diagnostic pathway

Formal diagnosis requires a sleep specialist (sleep physician or neurologist with sleep training). The sequence is:

1. Overnight polysomnography (PSG) — rules out obstructive sleep apnoea and other sleep disorders; provides baseline sleep architecture
2. Multiple Sleep Latency Test (MSLT) next morning — five nap opportunities at two-hour intervals; mean sleep latency ≤ 8 minutes plus two or more sleep-onset REM periods (SOREMPs) confirms narcolepsy
3. CSF hypocretin-1 (orexin-A) measurement — specialist-performed lumbar puncture; levels ≤ 110 pg/mL are diagnostic of narcolepsy Type 1 in atypical presentations

Sleep diary and actigraphy over seven to fourteen days before the MSLT confirm adequate prior sleep, which is mandatory for valid interpretation.

B. Evidence base — diagnostic workup and sleep testing

The Cochrane review of pharmacological treatment of narcolepsy and Bassetti et al (Lancet Neurology 2019) support the following hierarchy of evidence:

Modafinil has the strongest evidence base for EDS in narcolepsy: multiple RCTs demonstrate improved wakefulness, reduced sleep attacks, and better quality of life. The Cochrane review confirms superior efficacy versus placebo. Modafinil does not address cataplexy.

Methylphenidate and dexamphetamine have long-established efficacy from clinical series predating modern trial methodology. They carry greater cardiovascular and abuse-potential risks than modafinil and require Schedule 8 state authority in addition to PBS Authority.

Pitolisant (Wakix) — a histamine H3 receptor inverse agonist — has RCT evidence from the HARMONY trials showing improvements in both EDS and cataplexy frequency, making it useful when patients need treatment for both domains or when stimulants are poorly tolerated or contraindicated.

Sodium oxybate — the most effective agent for cataplexy and for consolidating nocturnal sleep — is supported by multiple RCTs demonstrating dramatic reductions in cataplexy attacks and EDS. Access in Australia requires the TGA Special Access Scheme due to its high abuse potential and cost (approximately $10,000–$30,000 per year without subsidy). It is initiated only by specialist sleep physicians in hospital contexts.

Scheduled napping: RCTs confirm that planned brief naps (15–20 minutes) reduce daytime sleepiness and improve performance in narcolepsy — the refreshing quality of brief naps in narcolepsy Type 1 distinguishes it clinically from idiopathic hypersomnia. Napping is foundational, not optional.

MSLT interpretation: The diagnostic value of the MSLT depends critically on adequate prior sleep and withdrawal of REM-suppressing drugs (antidepressants must typically be tapered two weeks before testing). False negatives occur when these conditions are not met — a key reason specialist coordination is essential.

C. Pharmacological management in Australia

Wake-promoting agents (EDS):

Agent	PBS pathway	Schedule	Key cautions
Modafinil (Modavigil)	Authority Required — narcolepsy, idiopathic hypersomnia, OSA residual EDS	S4	Headache, nausea, contraceptive interaction (CYP3A4)
Armodafinil (Nuvigil)	Authority Required — same indications	S4	Longer half-life; same class as modafinil
Methylphenidate (Ritalin, Concerta)	Authority Required — narcolepsy; state authority required	S8	Cardiovascular, growth (paeds), RTPM check
Dexamphetamine	Authority Required — narcolepsy; state authority required	S8	Higher abuse potential; RTPM check
Pitolisant (Wakix)	Authority Required — narcolepsy with EDS/cataplexy	S4	QT prolongation; CYP2D6; contraceptive interaction

Contraceptive counselling: Modafinil, armodafinil, and pitolisant all reduce hormonal contraceptive effectiveness via enzyme induction — advise patients using these agents to use non-hormonal contraception or intrauterine devices.

Schedule 8 and Real-Time Prescription Monitoring (RTPM): Methylphenidate and dexamphetamine require state-specific prescribing authority (Victoria SafeScript, Queensland QScript, and equivalent authorities in other states) in addition to PBS Authority. RTPM check at every prescription is mandatory in participating states.

Cataplexy agents:

• Venlafaxine 37.5–225 mg/day — most commonly used off-label in Australian practice; PBS general schedule for depression
• SSRIs (fluoxetine, sertraline) — moderate anticataplectic effect; off-label
• Clomipramine — effective but anticholinergic load limits use
• Sodium oxybate — most effective; TGA Special Access Scheme only
• Caution: never abruptly cease anticataplectic medications — rebound cataplexy (cataplexy storm) can be severe

D. Australian operations

MBS items relevant to general practice:

• Standard GP attendance: items 23, 36, 44 for assessment and medication review
• Telehealth equivalents for stable patients on established therapy (existing-relationship rule applies)
• Care planning: Chronic Disease Management Plan pathway (GPCCMP items 965/967) for allied health access — psychologist for mood and coping, occupational therapist for workplace adaptation

Sleep specialist referral:

• Public hospital sleep services exist in major centres but carry long waitlists
• Private sleep specialists: Medicare rebate items 110/116 (initial consult), 132/133 (review)
• Polysomnography (MBS item 12203) and MSLT (MBS item 12217) require a sleep specialist referral; home sleep studies are specifically not diagnostic for narcolepsy

Driving (Austroads 2022): Narcolepsy is an EDS condition requiring notification to the licensing authority. Austroads Assessing Fitness to Drive sets the standard: treated and documented stability over three to six months, specialist report, Maintenance of Wakefulness Test (MWT) for commercial licences, annual review. GPs must document advice given at each consultation. Commercial and heavy vehicle licensing may be incompatible with the diagnosis.

NDIS: Narcolepsy can qualify for NDIS support if it causes significant and permanent functional impact — supports for transport, workplace adaptation, and educational accommodation may be available.

Disability Discrimination Act: Workplace reasonable adjustments — flexible hours, permitted nap breaks — are legally supported. Encourage patients to understand their rights via the Australian Human Rights Commission.

Patient resources: Narcolepsy Australia provides peer support, education, and advocacy.

E. Special populations

Children and adolescents. Narcolepsy commonly begins between ages 10 and 17. Cataplexy in children may be atypical — persistent facial drooping rather than sudden falls. Weight gain is prominent at onset due to orexin’s metabolic role. Educational impact is significant; school accommodation plans and individual education plans are often warranted. Specialist paediatric sleep or neurology team should manage pharmacotherapy.

Pregnancy. Modafinil carries Category B3 — teratogenicity registry signals exist and it should ideally be tapered before conception with specialist guidance. Methylphenidate and amphetamines are Category B3 — avoid where possible. Sodium oxybate is also Category B3 and best avoided. SSRIs and venlafaxine for cataplexy require the usual pregnancy risk-benefit discussion with a specialist. Effective non-hormonal contraception is essential for all women of reproductive age using wake-promoting drugs.

Older adults. Sedating drug interactions are greater; careful review of polypharmacy. Modafinil is generally better tolerated than amphetamines in older patients. Cardiovascular monitoring is important with any stimulant.

Patients with comorbid obstructive sleep apnoea. OSA commonly coexists with narcolepsy and can compound EDS. CPAP should be optimised before attributing residual EDS solely to narcolepsy — modafinil is PBS-listed for OSA-related residual EDS on CPAP as well as narcolepsy.

When to escalate

Refer to a sleep specialist when:

• Epworth Sleepiness Scale score is above 10 and behavioural causes (insufficient sleep, OSA) have been excluded
• Clinical features suggest narcolepsy (cataplexy history, sleep paralysis, hallucinations)
• Excessive daytime sleepiness is significantly affecting safety, work, or driving
• Diagnosis of idiopathic hypersomnia is under consideration
• Driving fitness assessment is required

Refer urgently or to emergency when:

• Patient with known narcolepsy is in status cataplecticus (prolonged continuous cataplexy)
• Suicidal ideation is present — chronic sleep disorders carry increased suicide risk; Mental Health Care Plan (item 2715) and safety planning at diagnosis

What this article is and is not

This is general health information drawn from current Australian guidelines — Australasian Sleep Association, eTG, Austroads Fitness to Drive, and peer-reviewed pharmacological evidence — and the International Classification of Sleep Disorders (ICSD-3). It is not personal medical advice and does not create a doctor–patient relationship. Decisions about specific medications, sleep testing, and driving obligations are made with a sleep specialist and the individual’s treating GP.

For Australian consumer resources: Narcolepsy Australia, Sleep Health Foundation, HealthDirect — Narcolepsy, Better Health Channel.

For acute mental health support: Lifeline 13 11 14, Beyond Blue 1300 22 4636.

---

Sources cited

1. Australasian Sleep Association — clinical guidelines
2. Sleep Health Foundation
3. RACGP — Excessive daytime sleepiness in general practice
4. Therapeutic Guidelines (eTG) — Sleep disorders
5. Austroads — Assessing Fitness to Drive 2022
6. TGA — pitolisant and sodium oxybate access
7. Narcolepsy Australia
8. HealthDirect — Narcolepsy
9. Better Health Channel
10. International Classification of Sleep Disorders 3rd edition (ICSD-3)
11. Bassetti CL et al — Narcolepsy (Lancet Neurology 2019)
12. Cochrane — Pharmacological treatment of narcolepsy